Evidence map›Paper›PMID 26656699›Full record

ArticleJournal of virology2016

Investigating the Influence of Ribavirin on Human Respiratory Syncytial Virus RNA Synthesis by Using a High-Resolution Transcriptome Sequencing Approach.

Waleed Aljabr, Olivier Touzelet, Georgios Pollakis, Weining Wu, Diane C Munday, Margaret Hughes, Christiane Hertz-Fowler, John Kenny, Rachel Fearns, John N Barr and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Journal of virology · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Waleed AljabrInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Olivier TouzeletInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Georgios PollakisInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Weining WuInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Diane C MundayInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom.
Margaret HughesCentre for Genomic Research, University of Liverpool, Liverpool, United Kingdom.
Christiane Hertz-FowlerCentre for Genomic Research, University of Liverpool, Liverpool, United Kingdom.
John KennyCentre for Genomic Research, University of Liverpool, Liverpool, United Kingdom.
Rachel FearnsSchool of Medicine, Boston University, Boston, Massachusetts, USA.
John N BarrSchool of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom.
David A MatthewsSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom d.a.matthews@bristol.ac.uk julian.hiscox@liverpool.ac.uk.
Julian A HiscoxInstitute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom d.a.matthews@bristol.ac.uk julian.hiscox@liverpool.ac.uk.
University of Liverpool · GBHealth Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool · GBBoston University · USUniversity of Bristol · GBUniversity of Leeds · GB

Funding

Medical Research Council MR/K000276/1
6 · The paper itself

Abstract

unlabelledHuman respiratory syncytial virus (HRSV) is a major cause of serious respiratory tract infection. Treatment options include administration of ribavirin, a purine analog, although the mechanism of its anti-HRSV activity is unknown. We used transcriptome sequencing (RNA-seq) to investigate the genome mutation frequency and viral mRNA accumulation in HRSV-infected cells that were left untreated or treated with ribavirin. In the absence of ribavirin, HRSV-specific transcripts accounted for up to one-third of total RNA reads from the infected-cell RNA population. Ribavirin treatment resulted in a >90% reduction in abundance of viral mRNA reads, while at the same time no such reduction was detected for the abundance of cellular transcripts. The presented data reveal that ribavirin significantly increases the frequency of HRSV-specific RNA mutations, suggesting a direct influence on the fidelity of the HRSV polymerase. The presented data show that transitions and transversions occur during HRSV replication and that these changes occur in hot spots along the HRSV genome. Examination of nucleotide substitution rates in the viral genome indicated an increase in the frequency of transition but not transversion mutations in the presence of ribavirin. In addition, our data indicate that in the continuous cell types used and at the time points analyzed, the abundances of some HRSV mRNAs do not reflect the order in which the mRNAs are transcribed. IMPORTANCE: Human respiratory syncytial virus (HRSV) is a major pediatric pathogen. Ribavirin can be used in children who are extremely ill to reduce the amount of virus and to lower the burden of disease. Ribavirin is used as an experimental therapy with other viruses. The mechanism of action of ribavirin against HRSV is not well understood, although it is thought to increase the mutation rate of the viral polymerase during replication. To investigate this hypothesis, we used a high-resolution approach that allowed us to determine the genetic sequence of the virus to a great depth of coverage. We found that ribavirin did not cause a detectable change in the relative amounts of viral mRNA transcripts. However, we found that ribavirin treatment did indeed cause an increase in the number of mutations, which was associated with a decrease in virus production.

Indexed as

MutationTranscriptomeAntiviral AgentsGenome, ViralHigh-Throughput Nucleotide SequencingHumansInterferon-betaRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRibavirinRNA, ViralViral Plaque AssayVirus AttachmentVirus InternalizationVirus ReplicationAntiviral AgentsInterferon-betaRibavirinRNA, Viral

Identifiers

PMID26656699
PMCPMC4859727
OpenAlexW2344746684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.